Marinomed Biotechnologie has signed a licensing agreement with Boehringer Ingelheim to market Marinomed’s anti-viral nasal spray for treating the common cold in Europe (except Austria and UK), Russia and CIS, South America, parts of Asia, and Australia.
29 June, 2010
BICOLL GmbH and EMBL have announced the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.
23 June, 2010
Researchers have been awarded £1.8 million to examine whether the use of pesticides is hampering the cognitive functions of bees – and possibly hastening their demise.
22 June, 2010
The UK launch of Sativex®, GW Pharmaceuticals’ oromucosal spray for the treatment of spasticity caused by multiple sclerosis, has been announced.
21 June, 2010
Clinical results from a Phase IIb study have shown that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo in improving overall sleep efficiency in patients with primary insomnia.
18 June, 2010
Research identifying a novel, early biomarker for insulin resistance and glucose intolerance in a non-diabetic population has now been published.
17 June, 2010
Latest NICE cost–benefit guidance includes Sandoz’s Omnitrope® as one of seven recommended somatropin products to treat growth failure in children.
11 June, 2010
Researchers at the Marlene and Stewart Greenebaum Cancer Center have studied the involvement of ‘microtentacles’, or extensions of the plasma membrane of breast cancer cells, in how cancers spread to distant locations in the body.
11 June, 2010
Vital Therapies, Inc. (VTI) has announced that the first two subjects have been enrolled at King's College Hospital, London, in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe.
10 June, 2010
Stakeholders celebrate ten years of success of the EU regulation on orphan medicines at the European Parliament.
04 June, 2010
Amgen announced recently that Prolia (denosumab), a new type of osteoporosis treatment for post-menopausal women, has been granted marketing authorization in the UK.
03 June, 2010
Teva is investing £37 million to expand its Stouffville production plant and Ontario is providing a £4.25 million grant to Teva Canada, which will retain 182 workers and hire 20 more.
02 June, 2010